Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Total Debt (2017 - 2020)

Purple Biotech has reported Total Debt over the past 4 years, most recently at $24.4 million for Q2 2020.

  • Quarterly Total Debt rose 895.63% to $24.4 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $24.4 million through Jun 2020, up 895.63% year-over-year, with the annual reading at $554000.0 for FY2018, 72.47% down from the prior year.
  • Total Debt was $24.4 million for Q2 2020 at Purple Biotech, up from $2.5 million in the prior quarter.
  • Over five years, Total Debt peaked at $24.4 million in Q2 2020 and troughed at $554000.0 in Q4 2018.
  • The 4-year median for Total Debt is $2.2 million (2017), against an average of $5.8 million.
  • Year-over-year, Total Debt crashed 72.47% in 2018 and then surged 895.63% in 2020.
  • A 4-year view of Total Debt shows it stood at $2.0 million in 2017, then crashed by 72.47% to $554000.0 in 2018, then surged by 342.42% to $2.5 million in 2019, then surged by 895.63% to $24.4 million in 2020.
  • Per Business Quant, the three most recent readings for PPBT's Total Debt are $24.4 million (Q2 2020), $2.5 million (Q2 2019), and $554000.0 (Q4 2018).